News & Updates
Filter by Specialty:
Some COVID-19 patients see persistent lung disease 6 months after infection
Radiographic and physiologic signs of lung disease persist for up to 6 months after infection from COVID-19, reports a recent study.
Some COVID-19 patients see persistent lung disease 6 months after infection
24 Nov 2022
Low-carb vegan diet reduces weight, greenhouse gas emissions
Vegan and vegetarian diets that are low in carbohydrates reduce body weight as well as improve glycaemic control and blood pressure in individuals with type 2 diabetes (T2D), suggests a study, adding that a plant-based diet shows greater potential decrease in greenhouse gas emissions.
Low-carb vegan diet reduces weight, greenhouse gas emissions
23 Nov 2022
GLP-1 receptor agonists halt COPD exacerbations in T2D patients
Use of glucagon-like peptide 1 (GLP-1) receptor agonists or sodium-glucose co-transporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, helps prevent severe exacerbations of chronic obstructive pulmonary disease (COPD) in patients with type 2 diabetes (T2D), a UK study has shown.
GLP-1 receptor agonists halt COPD exacerbations in T2D patients
23 Nov 2022
Coffee intake lowers risk of endometrial cancer
Women who love to drink coffee will have more reason to do so following a study that reports an association between coffee consumption and a reduced risk of endometrial cancer, particularly among those with higher body mass index (BMI).
Coffee intake lowers risk of endometrial cancer
23 Nov 2022
Sleep disturbance comes in three in kids with new-onset epilepsy
New research has shown that there are three distinct phenotypes of sleep disturbance in children with newly diagnosed epilepsy: minimal, moderate, and severe.
Sleep disturbance comes in three in kids with new-onset epilepsy
23 Nov 2022
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
Patients with moderate-to-severe systemic lupus erythematosus (SLE) appear to fare well with anifrolumab, with a recent study showing that the drug has an acceptable long-term safety profile and helps maintain reductions in disease activity and glucocorticoid usage.